Marketdash
Back to News

Last Week's Biggest Large-Cap Losers: From Disappointing Earnings to Tariff Troubles

MarketDash Editorial Team
8 days ago
Ten large-cap stocks took a beating last week, led by Nutanix's 18% plunge after disappointing guidance. Find out which other major names stumbled and whether any are lurking in your portfolio.

Last week wasn't kind to some of the market's bigger names. If you're holding any of these ten large-cap stocks, you probably noticed some red in your portfolio between November 24 and November 28.

The Biggest Losers

Nutanix, Inc. (NTNX) took the top spot with an 18.06% decline after delivering a triple whammy of bad news. The cloud computing company reported first-quarter sales that missed expectations, issued weak second-quarter guidance, and lowered its 2026 sales outlook below what analysts were anticipating. Unsurprisingly, multiple analysts responded by cutting their price targets on the stock.

Burlington Stores, Inc. (BURL) dropped 11.09% after posting mixed third-quarter results. The real concern? The retailer revealed that store traffic fell off a cliff once the back-to-school shopping period ended, raising questions about consumer spending patterns heading into the holidays.

Zscaler, Inc. (ZS) slid 9.53% following its first-quarter earnings report. Mizuho analyst Gregg Moskowitz kept his Neutral rating but trimmed his price target from $325 to $310, suggesting the cybersecurity company's results didn't inspire much confidence.

Veeva Systems Inc. (VEEV) fell 3.79% for the week. Citigroup analyst Tyler Radke maintained his Buy rating but lowered his price forecast from $349 to $319, a notable haircut for the life sciences software provider.

Deere & Company (DE) decreased 2.75% after announcing it expects to take a pre-tax annual tariff hit of approximately $1.2 billion. That's a significant headwind for the agricultural equipment giant. Evercore ISI Group analyst David Raso responded by reducing his price target from $487 to $458.

Oracle Corporation (ORCL) declined 2.58% over the week. DA Davidson analyst Gil Luria maintained his Neutral rating but made a dramatic move, slashing his price forecast from $300 all the way down to $200—a one-third reduction that signals serious concerns about the database giant's valuation.

Warner Music Group Corp. (WMG) slumped 5.14% during the period, though no specific catalyst was reported for the music company's decline.

Ecopetrol S.A. (EC) fell 2.31% without any particular news driving the Colombian energy company's modest decline.

AECOM (ACM) decreased 1.77% for the week. The infrastructure consulting firm faced headwinds after Baird analyst Andrew Wittmann downgraded the stock from Outperform to Neutral the previous week, while keeping his price target at $143.

BeiGene Medicines Ltd. (ONC) rounded out the list with a 1.28% decline. Interestingly, this drop came despite positive news—the company announced it received FDA priority review for Sonrotoclax in relapsed or refractory mantle cell lymphoma after BTK Inhibitor therapy. Sometimes even good news doesn't stop a stock from sliding.

Whether these stocks are temporary stumbles or signs of deeper problems remains to be seen. But for anyone holding these names, last week was definitely one to forget.

Back to News

Last Week's Biggest Large-Cap Losers: From Disappointing Earnings to Tariff Troubles

MarketDash Editorial Team
8 days ago
Ten large-cap stocks took a beating last week, led by Nutanix's 18% plunge after disappointing guidance. Find out which other major names stumbled and whether any are lurking in your portfolio.

Last week wasn't kind to some of the market's bigger names. If you're holding any of these ten large-cap stocks, you probably noticed some red in your portfolio between November 24 and November 28.

The Biggest Losers

Nutanix, Inc. (NTNX) took the top spot with an 18.06% decline after delivering a triple whammy of bad news. The cloud computing company reported first-quarter sales that missed expectations, issued weak second-quarter guidance, and lowered its 2026 sales outlook below what analysts were anticipating. Unsurprisingly, multiple analysts responded by cutting their price targets on the stock.

Burlington Stores, Inc. (BURL) dropped 11.09% after posting mixed third-quarter results. The real concern? The retailer revealed that store traffic fell off a cliff once the back-to-school shopping period ended, raising questions about consumer spending patterns heading into the holidays.

Zscaler, Inc. (ZS) slid 9.53% following its first-quarter earnings report. Mizuho analyst Gregg Moskowitz kept his Neutral rating but trimmed his price target from $325 to $310, suggesting the cybersecurity company's results didn't inspire much confidence.

Veeva Systems Inc. (VEEV) fell 3.79% for the week. Citigroup analyst Tyler Radke maintained his Buy rating but lowered his price forecast from $349 to $319, a notable haircut for the life sciences software provider.

Deere & Company (DE) decreased 2.75% after announcing it expects to take a pre-tax annual tariff hit of approximately $1.2 billion. That's a significant headwind for the agricultural equipment giant. Evercore ISI Group analyst David Raso responded by reducing his price target from $487 to $458.

Oracle Corporation (ORCL) declined 2.58% over the week. DA Davidson analyst Gil Luria maintained his Neutral rating but made a dramatic move, slashing his price forecast from $300 all the way down to $200—a one-third reduction that signals serious concerns about the database giant's valuation.

Warner Music Group Corp. (WMG) slumped 5.14% during the period, though no specific catalyst was reported for the music company's decline.

Ecopetrol S.A. (EC) fell 2.31% without any particular news driving the Colombian energy company's modest decline.

AECOM (ACM) decreased 1.77% for the week. The infrastructure consulting firm faced headwinds after Baird analyst Andrew Wittmann downgraded the stock from Outperform to Neutral the previous week, while keeping his price target at $143.

BeiGene Medicines Ltd. (ONC) rounded out the list with a 1.28% decline. Interestingly, this drop came despite positive news—the company announced it received FDA priority review for Sonrotoclax in relapsed or refractory mantle cell lymphoma after BTK Inhibitor therapy. Sometimes even good news doesn't stop a stock from sliding.

Whether these stocks are temporary stumbles or signs of deeper problems remains to be seen. But for anyone holding these names, last week was definitely one to forget.